Balyasny Asset Management
KERX

Balyasny Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Balyasny Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-150,000
Closed -$698K – 2517
2017
Q4 		$698K Buy
+150,000
New +$827K ﹤0.01% 1446
2014
Q1 		– Sell
-928,464
Closed -$12M – 715
2013
Q4 		$12M Sell
928,464
-208,565
-18% -$2.49M 0.16% 173
2013
Q3 		$11.5M Buy
+1,137,029
New +$10.1M 0.15% 178

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Balyasny Asset Management's KERX Position: Q1 2018 in Review

Balyasny Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 150,000 shares — an estimated $698K sold.

Balyasny Asset Management first reported a position in KERX in Q3 2013 and held it in 3 quarters. The position peaked at $12M in Q4 2013. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Balyasny Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 150,000 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $698K.
  • Balyasny Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 3 quarters.
  • Balyasny Asset Management's Keryx Biopharmaceuticals Inc position peaked at $12M in Q4 2013.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Balyasny Asset Management's 13F filing for Q1 2018, filed 15 May 2018.